JP2017160233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017160233A5 JP2017160233A5 JP2017088732A JP2017088732A JP2017160233A5 JP 2017160233 A5 JP2017160233 A5 JP 2017160233A5 JP 2017088732 A JP2017088732 A JP 2017088732A JP 2017088732 A JP2017088732 A JP 2017088732A JP 2017160233 A5 JP2017160233 A5 JP 2017160233A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- group
- pharmaceutical composition
- change
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892881P | 2013-10-18 | 2013-10-18 | |
| US61/892,881 | 2013-10-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523266A Division JP6139788B2 (ja) | 2013-10-18 | 2014-10-16 | ピリミジンｆｇｆｒ４阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017160233A JP2017160233A (ja) | 2017-09-14 |
| JP2017160233A5 true JP2017160233A5 (enExample) | 2017-11-16 |
Family
ID=51842899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523266A Active JP6139788B2 (ja) | 2013-10-18 | 2014-10-16 | ピリミジンｆｇｆｒ４阻害剤 |
| JP2017088732A Pending JP2017160233A (ja) | 2013-10-18 | 2017-04-27 | ピリミジンｆｇｆｒ４阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523266A Active JP6139788B2 (ja) | 2013-10-18 | 2014-10-16 | ピリミジンｆｇｆｒ４阻害剤 |
Country Status (33)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| LT3057943T (lt) | 2013-10-18 | 2018-11-12 | Eisai R&D Management Co., Ltd. | Pirimidino fgfr4 slopikliai |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| PE20160546A1 (es) | 2013-10-25 | 2016-05-26 | Novartis Ag | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4 |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| MA38393B1 (fr) | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| WO2016168331A1 (en) * | 2015-04-14 | 2016-10-20 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| AU2016296877B2 (en) | 2015-07-20 | 2020-09-17 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as EGFR inhibitors and methods of treating disorders |
| CA2993022A1 (en) | 2015-07-20 | 2017-01-26 | Taipei Medical University | Chlorobenzene substituted azaaryl compounds |
| CN105418441A (zh) * | 2015-12-22 | 2016-03-23 | 中国工程物理研究院化工材料研究所 | 2,3-二氯-4-羟基苯胺的制备方法 |
| CN109071521B (zh) | 2016-01-08 | 2019-10-25 | 杭州英创医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| JP7372740B2 (ja) * | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
| WO2017198221A1 (zh) | 2016-05-20 | 2017-11-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| CN107400092B (zh) * | 2016-05-20 | 2021-08-24 | 浙江海正药业股份有限公司 | 嘧啶类衍生物及其制备方法和其在医药上的用途 |
| CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
| CA3034875C (en) * | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| KR102362648B1 (ko) | 2016-11-02 | 2022-02-11 | 노파르티스 아게 | Fgfr4 억제제 및 담즙산 격리제의 조합물 |
| WO2018090973A1 (zh) * | 2016-11-17 | 2018-05-24 | 广东众生药业股份有限公司 | Fgfr4抑制剂及其制备方法和应用 |
| KR101812266B1 (ko) | 2016-11-25 | 2017-12-27 | 한국과학기술연구원 | 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용 |
| CN108239069B (zh) * | 2016-12-26 | 2021-01-05 | 南京药捷安康生物科技有限公司 | 一种用于成纤维细胞生长因子受体的抑制剂及其用途 |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019024876A1 (zh) * | 2017-08-04 | 2019-02-07 | 上海和誉生物医药科技有限公司 | 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用 |
| CN109422760B (zh) * | 2017-09-01 | 2022-05-27 | 南京圣和药物研发有限公司 | Fgfr4抑制剂及其应用 |
| US11279697B2 (en) | 2017-09-05 | 2022-03-22 | Bioardis Llc | Aromatic derivative, preparation method for same, and medical applications thereof |
| SG11202006617RA (en) | 2018-01-10 | 2020-08-28 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of hepatocellular carcinoma |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| WO2019242689A1 (zh) * | 2018-06-22 | 2019-12-26 | 北京赛特明强医药科技有限公司 | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| RS65019B1 (sr) | 2019-05-10 | 2024-01-31 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
| AU2020274011B2 (en) | 2019-05-10 | 2024-02-15 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CN119241444A (zh) | 2019-06-17 | 2025-01-03 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112341344B (zh) * | 2019-08-09 | 2021-10-26 | 上海喀露蓝科技有限公司 | 一种激酶抑制剂中间体的制备方法 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020414132B2 (en) * | 2019-12-23 | 2024-02-15 | Beijing Scitech-Mq Pharmaceuticals Limited | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021230886A1 (en) | 2020-05-15 | 2021-11-18 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| WO2021231928A1 (en) | 2020-05-15 | 2021-11-18 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| CN113943251A (zh) * | 2020-07-16 | 2022-01-18 | 正大天晴药业集团股份有限公司 | 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途 |
| EP4226945A4 (en) | 2020-10-05 | 2024-10-23 | Chiome Bioscience, Inc | MEDICINES FOR THE TREATMENT OF CANCER |
| CN114621106A (zh) * | 2020-12-11 | 2022-06-14 | 重庆医药工业研究院有限责任公司 | 一种酪氨酸激酶药物中间体的制备方法 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN115490670A (zh) * | 2021-06-17 | 2022-12-20 | 浙江海正药业股份有限公司 | Fgfr4选择性抑制剂的盐及其制备方法和用途 |
| CN115504965A (zh) | 2021-06-23 | 2022-12-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物的晶型及其制备方法 |
| CN114276266B (zh) * | 2021-12-30 | 2024-10-11 | 兰州康鹏威耳化工有限公司 | 一种4-氨基-2-氟苯甲酰胺的制备方法 |
| CN114560815A (zh) * | 2022-03-04 | 2022-05-31 | 北京工业大学 | (2-((5-氯-取代苯基氨基嘧啶-2-基)氨基)苯基)氨基甲酸叔丁酯类衍生物 |
| CN116947825B (zh) * | 2022-04-14 | 2025-11-28 | 浙江海正药业股份有限公司 | Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途 |
| CN114835640B (zh) * | 2022-05-24 | 2024-02-13 | 中国药科大学 | 成纤维细胞生长因子受体抑制剂、制备方法及应用 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3881320D1 (de) * | 1987-09-28 | 1993-07-01 | Ciba Geigy Ag | Schaedlingsbekaempfungsmittel. |
| EE200000706A (et) | 1998-05-26 | 2002-06-17 | Warner-Lambert Company | Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| BRPI0413005A (pt) | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| MEP3808A (xx) | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| PT2114900T (pt) * | 2007-01-31 | 2019-01-17 | Ym Biosciences Australia Pty | Compostos à base de tiopirimidina e as suas utilizações |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| EP2523679A4 (en) | 2010-01-14 | 2013-07-24 | Univ Yale Inc | RECEPTORT SYROSINE KINASE (RTK) INHIBITOR AND ITS USE METHOD |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012136732A1 (en) | 2011-04-08 | 2012-10-11 | Ab Science | Treatment of multiple myeloma with masitinib |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| JP2015506944A (ja) | 2012-01-18 | 2015-03-05 | ジェネンテック， インコーポレイテッド | Ｆｇｆ１９修飾薬を使用する方法 |
| EP2821402B1 (en) | 2012-02-28 | 2019-08-21 | Astellas Pharma Inc. | Nitrogen-containing aromatic heterocyclic compound |
| DK2872491T3 (da) * | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| CA2908098A1 (en) * | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| WO2015006492A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| TW201605452A (zh) | 2013-08-28 | 2016-02-16 | 安斯泰來製藥股份有限公司 | 以嘧啶化合物作爲有效成分之醫藥組成物 |
| LT3057943T (lt) | 2013-10-18 | 2018-11-12 | Eisai R&D Management Co., Ltd. | Pirimidino fgfr4 slopikliai |
| BR112016008849B8 (pt) | 2013-10-25 | 2022-09-06 | Blueprint Medicines Corp | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| MA38393B1 (fr) * | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| WO2017198221A1 (zh) | 2016-05-20 | 2017-11-23 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| WO2017198149A1 (zh) | 2016-05-20 | 2017-11-23 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
-
2014
- 2014-10-16 LT LTEP14790956.8T patent/LT3057943T/lt unknown
- 2014-10-16 CN CN201480056358.4A patent/CN105899490B/zh active Active
- 2014-10-16 CN CN201910565163.7A patent/CN110354128A/zh active Pending
- 2014-10-16 PL PL14790956T patent/PL3057943T3/pl unknown
- 2014-10-16 CA CA2924206A patent/CA2924206C/en active Active
- 2014-10-16 TW TW103135880A patent/TWI597268B/zh active
- 2014-10-16 PT PT147909568T patent/PT3057943T/pt unknown
- 2014-10-16 EP EP14790956.8A patent/EP3057943B1/en active Active
- 2014-10-16 SG SG11201602069WA patent/SG11201602069WA/en unknown
- 2014-10-16 SM SM20180379T patent/SMT201800379T1/it unknown
- 2014-10-16 DK DK14790956.8T patent/DK3057943T3/en active
- 2014-10-16 MX MX2016004933A patent/MX378288B/es unknown
- 2014-10-16 SI SI201430792T patent/SI3057943T1/en unknown
- 2014-10-16 EP EP18167989.5A patent/EP3421457B1/en active Active
- 2014-10-16 JP JP2016523266A patent/JP6139788B2/ja active Active
- 2014-10-16 WO PCT/US2014/060857 patent/WO2015057938A1/en not_active Ceased
- 2014-10-16 WO PCT/US2014/060902 patent/WO2015057963A1/en not_active Ceased
- 2014-10-16 AU AU2014337291A patent/AU2014337291B9/en active Active
- 2014-10-16 PH PH1/2016/500676A patent/PH12016500676B1/en unknown
- 2014-10-16 NZ NZ717559A patent/NZ717559A/en unknown
- 2014-10-16 BR BR112016008110-2A patent/BR112016008110B1/pt active IP Right Grant
- 2014-10-16 PE PE2016000460A patent/PE20160679A1/es unknown
- 2014-10-16 UA UAA201605322A patent/UA116920C2/uk unknown
- 2014-10-16 MY MYPI2016000489A patent/MY184733A/en unknown
- 2014-10-16 RS RS20180834A patent/RS57444B1/sr unknown
- 2014-10-16 ES ES14790956.8T patent/ES2679521T3/es active Active
- 2014-10-16 JO JOP/2014/0297A patent/JO3515B1/ar active
- 2014-10-16 HR HRP20181129TT patent/HRP20181129T1/hr unknown
- 2014-10-16 HU HUE14790956A patent/HUE039268T2/hu unknown
- 2014-10-16 KR KR1020167009625A patent/KR101826015B1/ko active Active
- 2014-10-16 RU RU2016118981A patent/RU2715708C2/ru active
- 2014-10-16 AR ARP140103845A patent/AR098048A1/es active IP Right Grant
-
2016
- 2016-01-19 US US15/000,659 patent/US9434697B2/en active Active
- 2016-03-01 IL IL244373A patent/IL244373B/en active IP Right Grant
- 2016-04-18 CL CL2016000918A patent/CL2016000918A1/es unknown
- 2016-07-27 US US15/221,018 patent/US9730931B2/en active Active
-
2017
- 2017-04-27 JP JP2017088732A patent/JP2017160233A/ja active Pending
- 2017-06-20 US US15/627,851 patent/US10537571B2/en active Active
-
2018
- 2018-07-18 CY CY181100754T patent/CY1121129T1/el unknown
- 2018-11-27 AU AU2018271284A patent/AU2018271284B2/en active Active
-
2019
- 2019-12-17 US US16/717,080 patent/US10912774B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017160233A5 (enExample) | ||
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| JP2014500265A5 (enExample) | ||
| JP2006517939A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2005534623A5 (enExample) | ||
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
| JP2010529118A5 (enExample) | ||
| NO20091596L (no) | Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer | |
| JP2009534386A5 (enExample) | ||
| JP2020510661A5 (enExample) | ||
| JP2011529049A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2012516894A5 (enExample) | ||
| US20050032786A1 (en) | 1, 3-benzothiazinone derivatives and use thereof | |
| JP2019505529A5 (enExample) | ||
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| JP2015525207A5 (enExample) | ||
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| JP2018531241A5 (enExample) | ||
| PL1891029T3 (pl) | Związki organiczne do leczenia stanów zapalnych lub alergicznych | |
| SI3038622T1 (en) | Heterocyclic compounds and methods of use | |
| JP2013516480A5 (enExample) |